(Circulation. 1995;92:2044-2049.)
© 1995 American Heart Association, Inc.
Articles |
A Randomized Trial of Recombinant Staphylokinase Versus Alteplase for Coronary Artery Patency in Acute Myocardial Infarction
From the Center for Molecular and Vascular Biology, University of Leuven. Participating centers and core facilities are listed in the "Appendix."
Correspondence to D. Collen, MD, PhD, Center for Molecular and Vascular Biology, University of Leuven, Campus Gasthuisberg, O&N, Herestraat 49, B-3000 Leuven, Belgium.
Background Recombinant staphylokinase (STAR) was shown recently to offer promise for coronary arterial thrombolysis in patients with evolving myocardial infarction. The present multicenter randomized open trial was designed to assess the thrombolytic efficacy, safety, and fibrin specificity of STAR relative to accelerated alteplase (recombinant tissue-type plasminogen activator [RTPA]).
Methods and Results One hundred patients with evolving myocardial infarction of <6 hours' duration and with ST-segment elevation were allocated to accelerated and weight-adjusted RTPA over 90 minutes (52 patients) or to STAR (the first 25 patients to 10 mg and the next 23 patients to 20 mg given intravenously over 30 minutes). All patients received aspirin and intravenous heparin. The main end points were coronary artery patency and plasma fibrinogen levels at 90 minutes. Thrombolysis in Myocardial Infarction (TIMI) perfusion grade 3 at 90 minutes was achieved in 62% of STAR patients versus 58% of RTPA patients (risk ratio, 1.1; 95% CI, 0.76 to 1.5). With 10 mg STAR, TIMI grade 3 patency was 50% (risk ratio, 0.86; 95% CI, 0.54 to 1.4 versus RTPA); with 20 mg STAR, it was 74% (risk ratio, 1.3; 95% CI, 0.90 to 1.8 versus RTPA). Residual fibrinogen levels at 90 minutes were 118±47% (mean±SD) of baseline with STAR and 68±42% with RTPA (P<.0005). STAR therapy was not associated with an excess mortality or electric, hemorrhagic, mechanical, or allergic complications. However, patients developed antibody-mediated STAR-neutralizing activity from the second week after STAR treatment. As an addendum to the randomized study, 5 patients were given 40 mg STAR over 30 minutes, resulting in TIMI perfusion grade 3 at 90 minutes in 4 patients without fibrinogen breakdown (residual levels at 90 minutes of 105±8% of baseline).
Conclusions STAR appears to be at least as effective for early coronary recanalization as and significantly more fibrin-specific than accelerated RTPA in patients with evolving myocardial infarction.
Key Words: thrombolysis • myocardial infarction • plasminogen activators
This article has been cited by other articles:
 |
|
 |
|
  Q. Lian, S. J. Szarka, K. K. S. Ng, and S.-L. Wong Engineering of a Staphylokinase-based Fibrinolytic Agent with Antithrombotic Activity and Targeting Capability toward Thrombin-rich Fibrin and Plasma Clots J. Biol. Chem., July 11, 2003; 278(29): 26677 - 26686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-C. Wu, F. J. Castellino, and S.-L. Wong A Fast-acting, Modular-structured Staphylokinase Fusion with Kringle-1 from Human Plasminogen as the Fibrin-targeting Domain Offers Improved Clot Lysis Efficacy J. Biol. Chem., May 9, 2003; 278(20): 18199 - 18206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. M. Warmerdam, K. Vanderlick, P. Vandervoort, H. De Smedt, S. Plaisance, M. De Maeyer, and D. Collen Staphylokinase-Specific Cell-Mediated Immunity in Humans J. Immunol., January 1, 2002; 168(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Armstrong and D. Collen Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 1 Circulation, June 12, 2001; 103(23): 2862 - 2866. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Moons, I. Vanlinthout, I. Roelants, R. Moreadith, D. Collen, and H. J. Rapold Toxicology Studies with Recombinant Staphylokinase and with SY 161-P5, a Polyethylene Glycol-Derivatized Cysteine-Substitution Mutant Toxicol Pathol, April 1, 2001; 29(3): 285 - 291. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119 (2009): 253S - 277S. [Full Text] [PDF]
|
|
|
|
|
|
D. Collen, P. Sinnaeve, E. Demarsin, H. Moreau, M. De Maeyer, L. Jespers, Y. Laroche, and F. Van de Werf Polyethylene Glycol-Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial Infarction Circulation, October 10, 2000; 102(15): 1766 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Laroche, S. Heymans, S. Capaert, F. De Cock, E. Demarsin, and D. Collen Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes Blood, August 15, 2000; 96(4): 1425 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vanwetswinkel, S. Plaisance, Z. Zhi-yong, I. Vanlinthout, K. Brepoels, I. Lasters, D. Collen, and L. Jespers Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase Blood, February 1, 2000; 95(3): 936 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 1 - 13. [PDF]
|
|
|
|
|
|
N. Nagai, I. Vanlinthout, and D. Collen Comparative Effects of Tissue Plasminogen Activator, Streptokinase, and Staphylokinase on Cerebral Ischemic Infarction and Pulmonary Clot Lysis in Hamster Models Circulation, December 21, 1999; 100(25): 2541 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Moser, T. Nordt, K. Peter, J. Ruef, B. Kohler, M. Schmittner, R. Smalling, W. Kubler, and C. Bode Platelet Function During and After Thrombolytic Therapy for Acute Myocardial Infarction With Reteplase, Alteplase, or Streptokinase Circulation, November 2, 1999; 100(18): 1858 - 1864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.J. Van de Werf The ideal fibrinolytic: can drug design improve clinical results? Eur. Heart J., October 2, 1999; 20(20): 1452 - 1458. [PDF]
|
|
|
|
|
|
M. Rosenberg, W. Kingma, M. A. Fitzpatrick, and S. M. Richards Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients After Repeat Administration Blood, March 15, 1999; 93(6): 2081 - 2088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Szarka, E. G. Sihota, H. R. Habibi, and S.-L. Wong Staphylokinase as a Plasminogen Activator Component in Recombinant Fusion Proteins Appl. Envir. Microbiol., February 1, 1999; 65(2): 506 - 513. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Pislaru, C. Pislaru, M. Szilard, J. Arnout, and F. Van de Werf In vivo effects of contrast media on coronary thrombolysis J. Am. Coll. Cardiol., October 1, 1998; 32(4): 1102 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jenne, K. Brepoels, D. Collen, and L. Jespers High Resolution Mapping of the B Cell Epitopes of Staphylokinase in Humans Using Negative Selection of a Phage-Displayed Antigen Library J. Immunol., September 15, 1998; 161(6): 3161 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Schlott, K.-H. Guhrs, M. Hartmann, A. Rocker, and D. Collen NH2-terminal Structural Motifs in Staphylokinase Required for Plasminogen Activation J. Biol. Chem., August 28, 1998; 273(35): 22346 - 22350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. White and F. J. J. Van de Werf Thrombolysis for Acute Myocardial Infarction Circulation, April 28, 1998; 97(16): 1632 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vanderschueren, I. Van Vlaenderen, and D. Collen Intravenous Thrombolysis With Recombinant Staphylokinase Versus Tissue-Type Plasminogen Activator in a Rabbit Embolic Stroke Model Stroke, September 1, 1997; 28(9): 1783 - 1788. [Abstract] [Full Text]
|
|
|
|
|
|
B. Schlott, K.-H. Guhrs, M. Hartmann, A. Rocker, and D. Collen Staphylokinase Requires NH2-terminal Proteolysis for Plasminogen Activation J. Biol. Chem., February 28, 1997; 272(9): 6067 - 6072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, C. H. McCabe, C. M. Gibson, M. Ghali, R. F. Sequeira, G. R. McKendall, J. Breed, N. B. Modi, N. L. Fox, R. P. Tracy, et al. TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-Ranging Trial Circulation, January 21, 1997; 95(2): 351 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
D. Collen, F. De Cock, E. Demarsin, S. Jenne, I. Lasters, Y. Laroche, P. Warmerdam, and L. Jespers Recombinant Staphylokinase Variants With Altered Immunoreactivity: III: Species Variability of Antibody Binding Patterns Circulation, January 21, 1997; 95(2): 455 - 462. [Abstract] [Full Text]
|
|
|
|
|
|
D. V. Sakharov, H. R. Lijnen, and D. C. Rijken Interactions between Staphylokinase, Plasmin(ogen), and Fibrin. STAPHYLOKINASE DISCRIMINATES BETWEEN FREE PLASMINOGEN AND PLASMINOGEN BOUND TO PARTIALLY DEGRADED FIBRIN J. Biol. Chem., November 1, 1996; 271(44): 27912 - 27918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Collen, R. Bernaerts, P. Declerck, F. De Cock, E. Demarsin, S. Jenne, Y. Laroche, H. R. Lijnen, K. Silence, and M. Verstreken Recombinant Staphylokinase Variants With Altered Immunoreactivity: I: Construction and Characterization Circulation, July 15, 1996; 94(2): 197 - 206. [Abstract] [Full Text]
|
|
|
|
|
|
D. Collen, H. Moreau, L. Stockx, and S. Vanderschueren Recombinant Staphylokinase Variants With Altered Immunoreactivity: II: Thrombolytic Properties and Antibody Induction Circulation, July 15, 1996; 94(2): 207 - 216. [Abstract] [Full Text]
|
|
|
|
|
|
D. Collen Fibrin-Selective Thrombolytic Therapy for Acute Myocardial Infarction Circulation, March 1, 1996; 93(5): 857 - 865. [Full Text]
|
|
|
|
 |
|
 A BETTER THROMBOLYTIC AGENT IN THE WINGS? Journal Watch (General), October 31, 1995; 1995(1031): 5 - 5. [Full Text]
|
|